Released Nov 5, 2020, after the close
10-Q filed Nov 9, 2020, 40 days after period end · 0001162194-20-000107
Q3 2020 · 10-Q
Revenue$39.86M$39.86M +50.4% vs Q3 2019+53.0% vs Q2 2020
Net Income-$6.00M-$6.00M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.08-$0.08 N/M vs Q3 2019N/M vs Q2 2020
Gross Profit$20,799,000+50.3%
Operating Income-$5,464,000N/M
Operating Cash Flowderived-$4,599,000N/M
Free Cash Flowderived-$4,938,000N/M
Margins · derived
Gross margin52.2%−0.0 pt vs Q3 2019
Operating margin-13.7%+38.4 pt vs Q3 2019
Net margin-15.0%+33.6 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $39.86M | $26.50M | $28.96M | $24.75M |
| Net Income | -$6.00M | -$12.89M | -$14.75M | -$15.94M |
| EPS Diluted | -$0.08 | -$0.19 | -$0.38 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR